Engineering a Clinically Translatable Bioartificial Pancreas to Treat Type I Diabetes
Trends in Biotechnology, ISSN: 0167-7799, Vol: 36, Issue: 4, Page: 445-456
2018
- 67Citations
- 147Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations67
- Citation Indexes67
- 67
- CrossRef4
- Captures147
- Readers147
- 147
- Mentions1
- Blog Mentions1
- Blog1
Review Description
Encapsulating, or immunoisolating, insulin-secreting cells within implantable, semipermeable membranes is an emerging treatment for type 1 diabetes. This approach can eliminate the need for immunosuppressive drug treatments to prevent transplant rejection and overcome the shortage of donor tissues by utilizing cells derived from allogeneic or xenogeneic sources. Encapsulation device designs are being optimized alongside the development of clinically viable, replenishable, insulin-producing stem cells, for the first time creating the possibility of widespread therapeutic use of this technology. Here, we highlight the status of the most advanced and widely explored implementations of cell encapsulation with an eye toward translating the potential of this technological approach to medical reality.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0167779918300283; http://dx.doi.org/10.1016/j.tibtech.2018.01.007; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85042041466&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29455936; https://linkinghub.elsevier.com/retrieve/pii/S0167779918300283; https://dx.doi.org/10.1016/j.tibtech.2018.01.007
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know